Clinical, radiology, pathologic patterns and outcomes of vaping related pulmonary injury in a single institution; A case series - 12/11/20
, Jonathan Xian a , Daniel Rongo b , Michelle McDonald c , Daniel Ocasionez d , Reeba Mathew a , Rosa M. Estrada -Y- Martin a , Bela Patel a , Sujith V. Cherian a, ⁎ , Pushan P. Jani a Abstract |
Since March 2019, E-cigarette or Vaping product associated lung injury (EVALI) has become an ongoing epidemic with more 2600 cases reported in the span of a few months in the United States. EVALI is defined as acute lung injury that develops secondary to the use of e-cigarettes or vaping products within the previous 90 days after exlusion of other possible inciting factors. Vitamin E acetate is believed to play a significant role in its pathogenesis. Treatment involves use of corticosteroids and further avoidance of these products. We describe a case series of 8 patients with EVALI, their clinical course and outcomes. All patients showed an excellent response to corticosteroids. In our experience, prognosis of EVALI is excellent, with complete resolution of symptoms in patients who followed up at 8 weeks.
Le texte complet de cet article est disponible en PDF.Highlights |
• | EVALI is a public health hazard. |
• | Lung injury pattern can be seen with as little as one week exposure even in an otherwise healthy young population. |
• | Lipid laden macrophages on BAL may be evident, though not pathognomonic. |
• | May see a subpleural sparing pattern and ground glass opacities on radiologic imaging. |
• | Steroids may play a role in symptom resolution. |
Keywords : EVALI
Plan
Vol 173
Article 106153- novembre 2020 Retour au numéro
Article précédent
- Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation
- Jodie A. Schildkraut, Jack Gallagher, Kozo Morimoto, Christoph Lange, Charles Haworth, R. Andres Floto, Wouter Hoefsloot, David E. Griffith, Dirk Wagner, Jakko van Ingen, NTM-NET
- Combining biomarkers of clot resolution and alveolar basement membrane destruction predicts mortality in the ECLIPSE COPD cohort
- Jannie M.B. Sand, Sarah R. Rønnow, Lasse L. Langholm, Morten A. Karsdal, Tina Manon-Jensen, Ruth Tal-Singer, Bruce E. Miller, Jørgen Vestbo, Diana J. Leeming
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?